Capsaicin
As of the edition of 20 October 2026, Capsaicin is a small molecule: marketed, first approved in 1974 (CH); acts on TRPV1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Qutenza
- First approved
- 4 October 1974 (CH)
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- GRÜNENTHAL DO BRASIL FARMACÊUTICA LTDA.; 5 holders in all
- Registered trials
- 133, 10 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Lungs and airways; Infections; Injuries; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Capsaicin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | Q8NER1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 42 | 25 | 6 | 4 |
| Phase 1 | 19 | 16 | 3 | 0 |
| Phase 2 | 32 | 29 | 0 | 1 |
| Phase 3 | 23 | 16 | 3 | 2 |
| Phase 4 | 17 | 11 | 1 | 3 |
| All trials | 133 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| NeurogesX | Applicant and Lead sponsor of trials | 2002 to now |
| Grunenthal | Applicant | 2009 to now |
| Averitas Pharma | Acquired holder and Lead sponsor of trials | 2019 to now |